Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week phase 3 study of fluticasone propionate MDPI versus fluticasone propionate + salmeterol MDPI in persistent asthma
2014-001149-25Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of fluticasone propionate and salmeterol in persistent asthma (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline in trough FEV1 at week 12. Started Jun 2014; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2014-001149-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001149-25.